Skip to main content
Fig. 2 | Journal of Experimental & Clinical Cancer Research

Fig. 2

From: Neoadjuvant toripalimab combined with gemcitabine and cisplatin in resectable locally advanced head and neck squamous cell carcinoma (NeoTGP01): An open label, single-arm, phase Ib clinical trial

Fig. 2

Waterfall plot of the characteristic of treatment response (n = 18). Each column indicates one patient, ranging from the highest to the lowest rate of pathological response. Corresponding sequence numbers of patients are labeled below. Two dashed horizontal lines denote 50% and 90% pathological responses. Three (16.7%) patients achieved pCR at the primary site, five (27.8%) achieved MPR (two among which were near-pCR, 1%), three (16.7%) achieved PPR, and seven (38.8%) were NPR

Back to article page